Trials / Recruiting
RecruitingNCT06333652
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ravulizumab | Intravenous infusion 100 mg/ml |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
- First posted
- 2024-03-27
- Last updated
- 2025-11-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06333652. Inclusion in this directory is not an endorsement.